Cocrystal Pharma, Inc.
Close on Oct 19, 2026
- Market cap
- $13.05M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Quarterly results announced on Form 8-K, Item 2.02
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q4 FY2025 Ended Dec 31, 2025 | Mar 31, 2026 | Before market open | – | – | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 14, 2025 | Before market open | – | $-0.19 | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 14, 2025 | Before market open | – | $-0.20 | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 15, 2025 | Before market open | – | – | – |
| Q4 FY2024 Ended Dec 31, 2024 | Mar 31, 2025 | Before market open | – | – | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 13, 2024 | During market hours | – | $-0.49 | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 14, 2024 | Before market open | – | $-0.54 | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 13, 2024 | Before market open | – | $-0.39 | – |
| Q4 FY2023 Ended Dec 31, 2023 | Mar 28, 2024 | Before market open | – | – | – |
| Q3 FY2023 Ended Sep 30, 2023 | Nov 13, 2023 | Before market open | – | $-0.41 | – |
| Q2 FY2023 Ended Jun 30, 2023 | Aug 16, 2023 | During market hours | – | $-0.41 | – |
| Q1 FY2023 Ended Mar 31, 2023 | May 15, 2023 | Before market open | – | $-0.64 | – |
Press releases
Announcements Cocrystal Pharma filed with the SEC
Pharma Announces Last Subject Dosed in Phase 1b Human Challenge Study Evaluating CDI-988 for Norovirus Prevention and Treatment
Regulation FD disclosure · EX-99.1 to Form 8-K
Pharma Appoints Carol Brosgart, MD to its Board of Directors
Regulation FD disclosure · EX-99.1 to Form 8-K
Pharma Announces $5 Million Private Placement with OPKO Health
Material agreement · Unregistered share sale · Regulation FD disclosure · EX-99.1 to Form 8-K
Pharma Appoints James Sapirstein, Biopharma Industry Leader with Extensive Antiviral Development Experience, as Chief Executive Officer
Regulation FD disclosure · EX-99.1 to Form 8-K
Pharma Announces Discovery of Pan-Viral Inhibitors
Regulation FD disclosure · EX-99.1 to Form 8-K
Pharma Presentation at ICAR 2026 Highlights Mechanism of Action and Clinical Advancement of CDI-988 for the Prevention and Treatment
Regulation FD disclosure · EX-99.1 to Form 8-K
Pharma Receives FDA Fast Track Designation for CDI-988 for Norovirus Infection Treatment and Preventive
Regulation FD disclosure · EX-99.1 to Form 8-K
Pharma Reports 2025 Financial Results and Provides Updates on its Antiviral Drug-Development Programs
Results of operations · EX-99.1 to Form 8-K
Subjects Dosed in Cocrystal Pharma’s Phase 1b Study Evaluating CDI-988 for Norovirus Prevention and Treatment
Regulation FD disclosure · EX-99.1 to Form 8-K
Pharma’s First Oral Norovirus Protease Inhibitor CDI-988 to be Featured at the International Society for Antiviral Research Conference
Regulation FD disclosure · EX-99.1 to Form 8-K
Pharma Receives IRB Approval from Emory University School of Medicine for Phase 1b Human Challenge Study with CDI-988 for Prevention
Regulation FD disclosure · EX-99.1 to Form 8-K
Pharma to Present at the Noble Capital Markets’ 21 st Emerging Growth Equity Conference
Regulation FD disclosure · EX-99.1 to Form 8-K
Pharma Reports Third Quarter 2025 Financial Results and Provides Updates on its Antiviral Drug-Development Programs
Results of operations · EX-99.1 to Form 8-K
Pharma Insiders Purchase $1.03 Million in Private Placement Priced At-the-Market Under Nasdaq Rules
Material agreement · Unregistered share sale · Regulation FD disclosure · EX-99.1 to Form 8-K
Cocrystal Pharma Receives NIH SBIR Award to
Regulation FD disclosure · EX-99.1 to Form 8-K
Pharma, Inc. Announces Closing of Up To $13 Million Registered Direct
Material agreement · Unregistered share sale · Regulation FD disclosure · EX-99.2 to Form 8-K
Pharma Showcases CDI-988, the First Oral Antiviral in Development for Norovirus Infection, in a Podium Presentation at the International
Regulation FD disclosure · EX-99.1 to Form 8-K
Pharma, Inc. Announces Up To $13 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
Regulation FD disclosure · EX-99.1 to Form 8-K
Pharma Reports Second Quarter 2025 Financial Results and Provides Updates on its Antiviral Drug-Development Programs
Results of operations · EX-99.1 to Form 8-K
Pharma Presents Phase 1 Results for Pan-Viral Inhibitor CDI-988 at Department of Defense Medical Conference
Regulation FD disclosure · EX-99.1 to Form 8-K
EX-99.2 to Form 8-K
Regulation FD disclosure · EX-99.2 to Form 8-K
Pharma to Presents Data from Phase 1 Study of First-in-Class Norovirus Protease Inhibitor CDI-988 at the 9 th International
Regulation FD disclosure · EX-99.1 to Form 8-K
Pharma’s Novel Norovirus Antiviral to be Presented at Department of Defense Medical Conference
Regulation FD disclosure · EX-99.1 to Form 8-K
Pharma’s Investigational Drug Candidate CC-42344 Demonstrates Strong Antiviral Potency Against the 2024 Highly Pathogenic H5N1
Regulation FD disclosure · EX-99.1 to Form 8-K
Cocrystal Pharma Reports First Quarter 2025 Financial
Results of operations · EX-99.1 to Form 8-K
Pharma’s Norovirus Oral Antiviral Candidate Demonstrates Potent Activity Against the Emerging GII.17 Variants
Regulation FD disclosure · EX-99.1 to Form 8-K
EX-99.1 CHARTER to Form 8-K
Regulation FD disclosure · EX-99.1 CHARTER to Form 8-K
Pharma Reports 2024 Financial Results and Provides Updates on its Antiviral Drug-Development Programs
Results of operations · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
Pharma Reports Phase 1 Results with Oral, Broad-Acting Antiviral Drug CDI-988 for Prophylaxis and Treatment of Norovirus, Coronaviruses
Regulation FD disclosure · EX-99.1 to Form 8-K
Pharma to Extend Phase 2a Influenza Challenge Study with Oral PB2 inhibitor CC-42344
Regulation FD disclosure · EX-99.1 to Form 8-K
Pharma Reports Third Quarter 2024 Financial Results and Provides Updates on its Antiviral Drug-Development Programs
Results of operations · EX-99.1 to Form 8-K
Pharma’s Co-CEOs Highlight Pioneering Approach to Antiviral Drug Candidates Targeting Influenza and Coronaviruses as Fall Flu and
Regulation FD disclosure · EX-99.1 to Form 8-K
Pharma to Highlight Near-term Clinical Milestones During Presentations at Two Upcoming Investment Conferences
Regulation FD disclosure · EX-99.1 to Form 8-K
Pharma Reports Second Quarter 2024 Financial Results and Provides Updates on its Antiviral Drug-Development Programs
Results of operations · EX-99.1 to Form 8-K
Pharma Reports Favorable Results from Single-Ascending Dose Cohorts of Phase 1 Study with CDI-988, its Oral Pan-Viral Norovirus/Coronavirus
Regulation FD disclosure · EX-99.1 to Form 8-K
Broad-Spectrum Antiviral Currently in a Phase 2a Clinical Trial in Influenza A may be Effective Against the H5N1 Avian Influenza Strain
Regulation FD disclosure · EX-99.1 to Form 8-K
Pharma Reports First Quarter 2024 Financial Results and Provides Updates on its Antiviral Drug-Development Programs
Results of operations · EX-99.1 to Form 8-K
Completed in Phase 2a Study with Cocrystal Pharma’s Oral Antiviral Candidate CC-42344 for Pandemic and Seasonal Influenza
Regulation FD disclosure · EX-99.1 to Form 8-K
Pharma Reports 2023 Financial Results and Provides Updates on its Antiviral Drug-Development Programs
Results of operations · EX-99.1 to Form 8-K